Yen-Chun Liu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Peritoneal Dialysis

Hepatitis B Virus

Top Venues

Alimentary pharmacology & therapeutics

Journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yen-Chun Liu, Wen-Juei Jeng
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients. Alimentary pharmacology & therapeutics 57 (5) (2023)
Yen-Chun Liu, Wen-Juei Jeng, Rong-Nan Chien
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection. Alimentary pharmacology & therapeutics 58 (7) (2023)
Yen-Chun Liu, Wen-Juei Jeng
Letter: the probability of predicting HBV-specific CD8+ cell response derived from HLA-A2+ may not closely predict functional cure in Asian patients who stop nucleoside analogues. Alimentary pharmacology & therapeutics 56 (8) (2022)
Chien-Wei Peng, Wen-Juei Jeng, Hwai-I Yang, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. Journal of gastroenterology and hepatology 37 (11) (2022)
Yen-Chun Liu, Wen-Juei Jeng
Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg-negative chronic hepatitis B? Alimentary pharmacology & therapeutics 56 (3) (2022)
Wei Teng, Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Su
Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers 13 (7) (2021)